Impact News +++ atai Life Sciences and Beckley Psytech complete strategic combination to form AtaiBeckley (Proactive Investors) +++ ATAI LIFE Aktie -4,46%

BIO-TECHNE Aktie

>BIO-TECHNE Aktienkurs

51 EUR -4.7% (Tradegate)

Ask: 52 EUR / 200 Stück

Bid: 51.5 EUR / 200 Stück

Tagesumsatz: 140 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

BIO-TECHNE Aktie über LYNX handeln

Intraday

1 Jahr

>BIO-TECHNE Performance

1 Woche: -2,7%

1 Monat: 0%

3 Monate: +13,8%

6 Monate: +21,0%

1 Jahr: -21,9%

laufendes Jahr: -23,0%

>BIO-TECHNE Aktie

Name:

BIO-TECHNE CORP. DL-,01

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US09073M1045 / A12ENG

Symbol/ Ticker:

TE1 (Frankfurt) / TECH (NASDAQ)

Kürzel:

FRA:TE1, ETR:TE1, TE1:GR, NASDAQ:TECH

Index:

S&P500

Webseite:

https://www.bio-techne.co..

Profil:

Bio-Techne Corporation is a leading developer and ..
>Volltext..

Marktkapitalisierung:

8300.65 Mio. EUR

Unternehmenswert:

8540.51 Mio. EUR

Umsatz:

1061.44 Mio. EUR

EBITDA:

327.67 Mio. EUR

Nettogewinn:

63.85 Mio. EUR

Gewinn je Aktie:

0.4 EUR

Schulden:

386.46 Mio. EUR

Liquide Mittel:

141.15 Mio. EUR

Operativer Cashflow:

250.26 Mio. EUR

Bargeldquote:

0.92

Umsatzwachstum:

-4.32%

Gewinnwachstum:

-60.31%

Dividende je Aktie:

0.27 EUR

Dividendenrendite:

0.52%

Dividendenschätzung:

0.52%

Div. Historie:

18.08.25 - 0.06863999€
19.05.25 - 0.06863999€

>weitere anzeigen...

Insiderhandel:

Suchwörter:

BIO-TECHNE, BIO TECHNE

Letzte Datenerhebung:

05.11.25

>BIO-TECHNE Kennzahlen

Aktien/ Unternehmen:

Aktien: 155.69 Mio. St.

Frei handelbar: 98.84%

Leerverk. Aktien: 4.46%

Rückkaufquote: 2.35%

Mitarbeiter: 3100

Umsatz/Mitarb.: 0.34 Mio. EUR

Analysten:

Analystenrating: Buy

Kursziel: 10.08%

Bewertung:

KGV: 138.97

KGV lG: 30.73

KUV: 8.27

KBV: 5.09

PEG-Ratio: -

EV/EBITDA: 26.06

Rentabilität:

Bruttomarge: 66.44%

Gewinnmarge: 6.02%

Operative Marge: 21.86%

Managementeffizenz:

Gesamtkaprendite: 2.73%

Eigenkaprendite: 3.68%

>BIO-TECHNE Peer Group

Es sind 597 Aktien bekannt.

>BIO-TECHNE Chart & Kurs - NASDAQ

>BIO-TECHNE News

05.11.25 - 18:15	TECH Stock Falls on Q1 Earnings Meet, Revenues Miss, Margins Up (Zacks)
	Bio-Techne's Q1 earnings meet expectations, but revenues slip 1%, sending shares lower despite stronger margins....

05.11.25 - 17:24	Bio-Techne verfehlt Q1-Prognosen 2025 – Aktie bricht ein (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

05.11.25 - 13:42	Bio-Techne Corp. Q1 Profit Increases, Inline With Estimates (AFX)
	WASHINGTON (dpa-AFX) - Bio-Techne Corp. (TECH) reported a profit for its first quarter that Increases, from the same period last year in line with the Street estimates.The company's bottom line to......

05.11.25 - 12:57	Bio-Techne declares $0.08 dividend (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

05.11.25 - 12:42	Bio-Techne Non-GAAP EPS of $0.42 in-line, revenue of $286.6M misses by $4.74M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

05.11.25 - 12:33	BIO-TECHNE DECLARES DIVIDEND (PR Newswire)
	MINNEAPOLIS, Nov. 5, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended September 30, 2025. The quarterly dividend will be payable November 28, 2025, to all common......

05.11.25 - 12:33	Bio-Techne Releases First Quarter Fiscal 2026 Results (PR Newswire)
	MINNEAPOLIS, Nov. 5, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the first quarter ended September 30, 2025. First Quarter FY2026 Highlights First quarter reported and organic revenue decreased 1% to $286.6 million. GAAP earnings per......

04.11.25 - 15:03	AI-Powered Spatial Biology Workflow from Bio-Techne and Nucleai Enables Predictive Biomarker Discovery in Melanoma Patients (PR Newswire)
	Clinical trial data demonstrates how Bio-Techne's spatial biology technology and Nucleai's AI-powered multimodal platforms can identify predictive biomarkers in immunotherapy and targeted therapy-treated melanoma patients. Bio-Techne's COMET™ platform and Nucleai's multimodal spatial......

03.11.25 - 13:03	ScaleReady Announces a G-Rex® Grant has been awarded to Sonoma Biotherapeutics (PR Newswire)
	ST. PAUL, Minn., Nov. 3, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that Sonoma Biotherapeutics has been awarded a $300,000 G-Rex® Grant. SonomaBio's G-Rex® Grant will enable expeditious......

28.10.25 - 11:33	Bio-Techne Launches ProximityScope™ Assay on the BOND RX platform from Leica Biosystems to Advance Spatial Protein-Protein Interactions Research (PR Newswire)
	Visualizes functional protein-protein interactions directly within fixed tissue at subcellular resolution Enables simultaneous detection of protein proximity, RNA, and proteins on the same tissue section Automates spatial multiomic workflows with the BOND RX platform from Leica Biosystems......

23.10.25 - 15:00	Bio-Techne Q1 Earnings Preview: What′s in Store for the Stock? (Zacks)
	TECH's Q1 results could reflect steady Protein Sciences growth but pressure in Spatial Biology amid NIH and biotech funding uncertainty....

23.10.25 - 13:01	ScaleReady Announces multiple G-Rex® Grants have been awarded to leading investigators at Children′s National Hospital (PR Newswire)
	ST. PAUL, Minn., Oct. 23, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady, announced four G-Rex Grants have been awarded to faculty members at Children's National Hospital. The funding, totaling......

15.10.25 - 19:21	ClearBridge Mid Cap Strategy outperforms benchmark in Q3, adds QXO and Bio-Techne, exits ATS (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

15.10.25 - 13:01	Bio-Techne to Host Conference Call on November 5, 2025, to Announce First Quarter Fiscal 2026 Financial Results (PR Newswire)
	MINNEAPOLIS, Oct. 15, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, November 5, 2025, at 8:00 a.m. CST to review its first quarter fiscal 2026 financial results. Access to the discussion may......

14.10.25 - 14:54	Earnings Preview: What to Expect From Bio-Technes Report (Barchart)
	Bio-Techne will release its first-quarter earnings soon, and analysts anticipate the bottom line to remain unchanged year over year....

09.10.25 - 13:03	Bio-Techne and Oxford Nanopore Technologies Expand Agreement to Accelerate Development of Genetics Portfolio Through 2032 (PR Newswire)
	Grants Bio-Techne expanded commercial rights to develop a portfolio of genetics products beyond the recently launched AmplideX® Nanopore Carrier Plus Kit Establishes a framework to define and propose future portfolios Extends collaboration through 2032, reinforcing Bio-Techne's......

08.10.25 - 16:00	Should You Continue to Hold Bio-Techne Stock in Your Portfolio? (Zacks)
	TECH drives growth via acquisitions, international strength and innovation. However, it faces macro pressures and rising competition....

08.10.25 - 00:42	5 Analysts Assess Bio-Techne: What You Need To Know (Benzinga)
	Latest Ratings for TECH DateFirmActionFromTo Feb 2022SVB LeerinkMaintainsOutperform Sep 2021KeybancUpgradesSector WeightOverweight Jun 2021SVB LeerinkMaintainsOutperform View More Analyst Ratings for TECH View the Latest Analyst Ratings read more...

29.09.25 - 16:00	Bio-Techne Stock Climbs on Advances in Spatial Biology Solutions (Zacks)
	TECH shares rise as advances in RNAscope and COMET spotlight new roles in lymphoid malignancy diagnostics....

26.09.25 - 12:33	Bio-Techne Advances Spatial Biology Solutions Bridging Translational Research to Clinical Applications (PR Newswire)
	RNAscope™ technology and the Lunaphore COMET™ enable simultaneous RNA and protein detection on the same tissue section Technologies support spatial multiomic analysis and deeper insights for pathology workflows Research highlights potential role in clinical utility workflows for lymphoid......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Die Sprache des Baus braucht man manchmal auch im Management. - Mag. Dr. Martin Kriegner

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram